These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 31170709

  • 1. Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
    Langmans C, Cornillie J, van Cann T, Wozniak A, Hompes D, Sciot R, Debiec-Rychter M, Vandenbempt I, Schöffski P.
    Oncol Res Treat; 2019; 42(7-8):396-404. PubMed ID: 31170709
    [Abstract] [Full Text] [Related]

  • 2. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
    Schöffski P.
    Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
    [Abstract] [Full Text] [Related]

  • 3. Influence of age and subtype in outcome of operable liposarcoma.
    Greto D, Saieva C, Loi M, Terziani F, Visani L, Garlatti P, Lo Russo M, Muntoni C, Becherini C, Topulli J, Campanacci D, Beltrami G, Scoccianti G, Muratori F, Bonomo P, Desideri I, Francolini G, Livi L.
    Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R, Marrari A, Marchetti S, Mussi C, Balzarini L, Lutman FR, Daolio P, Bastoni S, Bertuzzi AF, Quagliuolo V, Santoro A.
    Drug Des Devel Ther; 2015 Apr; 9():5785-91. PubMed ID: 26604682
    [Abstract] [Full Text] [Related]

  • 5. Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
    Matsuda S, Tanaka K, Kawano M, Iwasaki T, Itonaga I, Tsumura H.
    Medicine (Baltimore); 2020 Jan; 99(2):e18689. PubMed ID: 31914068
    [Abstract] [Full Text] [Related]

  • 6. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
    Stacchiotti S, Van der Graaf WTA, Sanfilippo RG, Marreaud SI, Van Houdt WJ, Judson IR, Gronchi A, Gelderblom H, Litiere S, Kasper B.
    Cancer; 2022 Aug 01; 128(15):2932-2938. PubMed ID: 35561319
    [Abstract] [Full Text] [Related]

  • 7. Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
    Assi T, Ngo C, Faron M, Verret B, Lévy A, Honoré C, Hénon C, Le Péchoux C, Bahleda R, Le Cesne A.
    Curr Treat Options Oncol; 2023 Nov 01; 24(11):1598-1613. PubMed ID: 37843627
    [Abstract] [Full Text] [Related]

  • 8. Differences in recurrence and survival of extremity liposarcoma subtypes.
    Vos M, Koseła-Paterczyk H, Rutkowski P, van Leenders GJLH, Normantowicz M, Lecyk A, Sleijfer S, Verhoef C, Grünhagen DJ.
    Eur J Surg Oncol; 2018 Sep 01; 44(9):1391-1397. PubMed ID: 29673808
    [Abstract] [Full Text] [Related]

  • 9. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY.
    Eur J Cancer; 2010 Jan 01; 46(1):72-83. PubMed ID: 19853437
    [Abstract] [Full Text] [Related]

  • 10. Differential sensitivity of liposarcoma subtypes to chemotherapy.
    Jones RL, Fisher C, Al-Muderis O, Judson IR.
    Eur J Cancer; 2005 Dec 01; 41(18):2853-60. PubMed ID: 16289617
    [Abstract] [Full Text] [Related]

  • 11. Primary Extremity Liposarcoma: MRI Features, Histopathology, and Clinical Outcomes.
    Wortman JR, Tirumani SH, Jagannathan JP, Tirumani H, Shinagare AB, Hornick JL, Ramaiya NH.
    J Comput Assist Tomogr; 2016 Dec 01; 40(5):791-8. PubMed ID: 27224232
    [Abstract] [Full Text] [Related]

  • 12. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD.
    Cancer; 2019 Aug 01; 125(15):2610-2620. PubMed ID: 31173362
    [Abstract] [Full Text] [Related]

  • 13. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X.
    Cancer Cytopathol; 2014 Feb 01; 122(2):128-37. PubMed ID: 24227706
    [Abstract] [Full Text] [Related]

  • 14. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort.
    Hoffman A, Lazar AJ, Pollock RE, Lev D.
    Drug Resist Updat; 2011 Feb 01; 14(1):52-66. PubMed ID: 21169051
    [Abstract] [Full Text] [Related]

  • 15. TRAbectedin in adVanced rEtroperitoneal well differentiated/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group.
    Fabbroni C, Grignani G, Vincenzi B, Fumagalli E, De Pas TM, Mazzocca A, Pantaleo MA, Brunello A, Baldi GG, Boglione A, Fatigoni S, Berruti A, Giordano M, Marrari A, Dei Tos AP, Alberton AS, Aliberti S, Carlucci L, Rulli E, Casali PG, Sanfilippo R.
    ESMO Open; 2024 Aug 01; 9(8):103667. PubMed ID: 39121815
    [Abstract] [Full Text] [Related]

  • 16. Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.
    Kawaguchi K, Nakano K, Urasaki T, Fukuda N, Taira S, Ono M, Tomomatsu J, Nishizawa M, Ae K, Matsumoto S, Takahashi S.
    In Vivo; 2019 Aug 01; 33(5):1609-1614. PubMed ID: 31471412
    [Abstract] [Full Text] [Related]

  • 17. Managing Liposarcomas: Cutting Through the Fat.
    Manji GA, Schwartz GK.
    J Oncol Pract; 2016 Mar 01; 12(3):221-7. PubMed ID: 26962163
    [Abstract] [Full Text] [Related]

  • 18. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
    Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A.
    Clin Oncol (R Coll Radiol); 2018 Jul 01; 30(7):448-454. PubMed ID: 29550245
    [Abstract] [Full Text] [Related]

  • 19. Current management options for liposarcoma and challenges for the future.
    Kollár A, Benson C.
    Expert Rev Anticancer Ther; 2014 Mar 01; 14(3):297-306. PubMed ID: 24397249
    [Abstract] [Full Text] [Related]

  • 20. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH, Mouritsen LS, Elowsson C, Krarup-Hansen A, Safwat A.
    Acta Oncol; 2015 Jan 01; 54(1):34-40. PubMed ID: 25263179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.